Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 15 - 21 |
| Number of pages | 7 |
| Journal | Menopause |
| Volume | 20 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2013 |
Cite this
}
Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. / Bell, Robin Jean; Fradkin, Pam; Schwarz, Max Allan; Davis, Susan Ruth.
In: Menopause, Vol. 20, No. 1, 2013, p. 15 - 21.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis
AU - Bell, Robin Jean
AU - Fradkin, Pam
AU - Schwarz, Max Allan
AU - Davis, Susan Ruth
PY - 2013
Y1 - 2013
N2 - Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation
AB - Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation
UR - http://www.ncbi.nlm.nih.gov/pubmed/22948136
U2 - 10.1097/gme.0b013e3182610cab
DO - 10.1097/gme.0b013e3182610cab
M3 - Article
VL - 20
SP - 15
EP - 21
JO - Menopause
JF - Menopause
SN - 1072-3714
IS - 1
ER -